In April last year, Bayer AG Chief Executive Werner Baumann was on defense. The architect of one of the most disastrous acquisitions in German corporate history, he had become the country’s first chief executive to lose a vote of confidence by shareholders. Almost a year later, with the German chemicals and pharmaceuticals company closer to settling more than 42,000 lawsuits inherited from its acquisition of U.S. agriculture giant Monsanto Co., and with a group-wide restructuring under way, investors say Mr. Baumann might...

Source: Wall Street Journal February 10, 2020 11:05 UTC